Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

Abstract A novel combination of capecitabine, oxaliplatin, and bevacizumab was evaluated in colorectal cancer patients enrolled in a phase II clinical trial. In this retrospective analysis, plasma samples from patients receiving capecitabine, oxaliplatin, and bevacizumab were analyzed to investigate...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Yingmiao Liu, Mark D. Starr, Anuradha Bulusu, Herbert Pang, Nan Soon Wong, Wanda Honeycutt, Anthony Amara, Herbert I. Hurwitz, Andrew B. Nixon
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2013-04-01
Rangatū:	Cancer Medicine
Ngā marau:	Angiome bevacizumab biomarker chemotherapy colorectal cancer
Urunga tuihono:	https://doi.org/10.1002/cam4.71
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!